Patents by Inventor Gizella Bartáné Szalai

Gizella Bartáné Szalai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9994525
    Abstract: The present invention relates to new histamine H3 (H3) receptor subtype selective ligands of the general formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and the use of these compounds as medicaments for treatment and/or prevention of conditions which require modulation of H3 receptors. The invention also cover the combinations of a compound of the general formula (I) and an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: June 12, 2018
    Assignee: Richter Gedeon Nyrt.
    Inventors: Gizella Bartáné Szalai, Gäbor András Wágner, Béla Kiss, Éva Schmidt, Ottília Balázs, Noémi Nagy
  • Publication number: 20160009645
    Abstract: The present invention relates to new histamine H3 (H3) receptor subtype selective ligands of the general formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and the use of these compounds as medicaments for treatment and/or prevention of conditions which require modulation of H3 receptors. The invention also cover the combinations of a compound of the general formula (I) and an acetylcholinesterase inhibitor.
    Type: Application
    Filed: March 6, 2014
    Publication date: January 14, 2016
    Inventors: Gizella BARTÁNÉ SZALAI, Gábor András WÁGNER, Béla KISS, Éva SCHMIDT, Ottília BALÁZS, Noémi NAGY
  • Publication number: 20150284338
    Abstract: Our invention relates to trans-(4-{4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl}-5,6-dichloro-pyrimidin-2-yl)-methylamine dihydrochloride monohydrate, the process for the synthesis of this compound, the new (4,5-dichloro-6-piperazin-1-yl-pyirimidin-2-yl)-methylamine monohydrochlorid used as starting material in this synthesis, as well as the industrial process for the synthesis of trans-N-(4- {2-[4-(5,6-dichloro-2-methyl-amino-pyirimidin-4-yl-)piperazin-1-yl]-ethly}cyclohexyl-propionamide starting from trans-(4-{4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl}-5,6-dichloro-pyrimidin-2-yl)-methylamine dihydrochloride monohydrate.
    Type: Application
    Filed: November 20, 2013
    Publication date: October 8, 2015
    Applicant: Richter Gedeon Nyrt.
    Inventors: Krisztina Szavicskó, György Domány, László Czibula, Gizella Bartáné Szalai, László Dobay, Éva Werkné Pap
  • Patent number: 8802672
    Abstract: The present invention relates to new dopamine D3 and D2 ligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: August 12, 2014
    Assignee: Richter Gedeon Nyrt.
    Inventors: Gizella Bartane Szalai, Eva Againe Csongor, Gyorgy Domany, Istvan Gyertyan, Bela Kiss, Judit Laszy, Katalin Saghy, Eva Schmidt, Sandor Farkas, Zsolt Komlodi
  • Publication number: 20120059034
    Abstract: The invention relates to novel crystalline hydrate, amorphous and crystalline polymorphic forms of 2-[4-(4-Fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazole-6-yl)-acetamide (I) (radiprodil). Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.
    Type: Application
    Filed: March 1, 2010
    Publication date: March 8, 2012
    Inventors: Ádám Demeter, Zoltán Német, András Nemes, Ferenc Sebok, Gizella Bartáné Szalai, László Czibula
  • Publication number: 20110112093
    Abstract: The present invention relates to new dopamine D3 and D2 ligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.
    Type: Application
    Filed: December 28, 2010
    Publication date: May 12, 2011
    Inventors: Gizella Bartane Szalai, Eva Againe Csongor, Gyorgy Domany, Istvan Gyertyan, Bela Kiss, Judit Laszy, Katalin Saghy, Eva Schmidt, Sandor Farkas, Zsolt Komlodi
  • Patent number: 7875610
    Abstract: The present invention relates to new dopamine D3 and D2 ligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: January 25, 2011
    Assignee: Richter Gedeon Nyrt.
    Inventors: Gizella Bartane Szalai, Eva Againe Csongor, Gyorgy Domany, Istvan Gyertyan, Bela Kiss, Judit Laszy, Katalin Saghy, Eva Schmidt, Sandor Farkas, Zsolt Komlodi
  • Publication number: 20090170901
    Abstract: The new benzoyl urea derivatives of formula (I) wherein the meaning of X and Y independently are hydrogen atom, hydroxy, benzyloxy, amino, nitro, C1-C4 alkylsulfonamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkoxy, aroyl-carbamoyl optionally substituted with halogen atom or C1-C4 alkyl or C1-C4 alkoxycarbonyl group, or the neighboring X and Y groups optionally form together with one or more identical or different additional hetero atom and —CH? and/or —CH2— groups an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably morpholine, pyrrole, pyrrolidine, oxo- or thioxo-pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazolidine, oxo- or thioxo-imidazole or imidazolidine, 1,4-oxazine, oxazole, oxazolidine, triazole, oxo- or thioxo-oxazolidine, or 3-oxo-1,4-oxazine ring, V and Z independently are hydrogen or halogen atom, cyano, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl, hydroxy o
    Type: Application
    Filed: July 21, 2005
    Publication date: July 2, 2009
    Inventors: Istvan Borza, Gizella Bartané Szalai, Eva Bozo, Csilla Acsné Kiss, Csilla Horvath, Sandor Farkas, Jozsef Nagy, Sandor Kolok
  • Publication number: 20090143398
    Abstract: The present invention relates to new dopamine D3 and D2 ligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.
    Type: Application
    Filed: December 3, 2008
    Publication date: June 4, 2009
    Inventors: Gizella Bartane Szalai, Eva Againe Csongor, Gyorgy Domany, Istvan Gyertyan, Bela Kiss, Judit Laszy, Katalin Saghy, Eva Schmidt, Sandor Farkas, Zsolt Komlodi
  • Patent number: 7435744
    Abstract: The present invention relates to a compound of formula (I): wherein: V and U are hydrogen, halogen, C1-C4 alkylamino, or together form a group that contains one or more heteroatoms, and that taken together with one or more: (a) hydrogen atoms; (b) carbon atoms; (c) —CH? groups; (d) —CH2— groups; or (e) additional heteroatoms of the same or different type; or any combination thereof, form a 4-7 membered homocyclic or heterocyclic ring, wherein the homocyclic or heterocyclic ring may combine with the phenyl group to form a bicyclic ring, and wherein the homocyclic or heterocyclic ring or the bicyclic ring may contain one or more oxo, thioxo, amino, mercapto, trifluoromethyl, C1-C4 alkyl, ?S or —SH groups; W: is —CO—, —CH2— or —CH2—(C1-C4 alkyl)-; X: is —CO—; Y: is —O—, C1-C4 alkylene, C1-C4 alkynylene, cycloalkylene, aminocarbonyl, —NH—, —N(C1-C4 alkyl)-, -C1-C4 alkylene-N(C1-C4 alkyl)-, —CH2O—, —CH(OH)— or —OCH2—; Z: is hydrogen, halogen, nitro, amino, C1-C4 alkyl, C1-C4 alkoxy, cyano, trifluorometh
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: October 14, 2008
    Assignee: Gedeon Richter Vegyeszeti Gyar RT
    Inventors: Gyorgy Domány, Csilla Horváth, Gizella Bartáné Szalai, József Nagy, Sándor Kolok, Éva Kovácsné Bozó, István Borza, István Vágó, Attila Bielik, Györgyi Ignáczné Szendrei, György Keserü, Sándor Farkas
  • Patent number: 7378431
    Abstract: Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I) wherein one of the neighboring R1, R2, R3 and R4 groups is hydroxy, and the others are each hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups, X is NH—, Y is a nitrogen atom, or pharmaceutically acceptable salts thereof formed with acids or bases.
    Type: Grant
    Filed: December 29, 2004
    Date of Patent: May 27, 2008
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Csilla Horvath, Sandor Farkas, György Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Patent number: 7375116
    Abstract: Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I) where two of the neighboring R1, R2, R3 and R4 groups form an imidazole ring fused to the benzene ring of the indole nucleus, and the other two of R1, R2, R3 and R4 groups are hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups, X is NH—, Y is a —CH— group, or pharmaceutically acceptable salts thereof formed with acids or bases.
    Type: Grant
    Filed: December 29, 2004
    Date of Patent: May 20, 2008
    Assignee: Richter Gedeon Vegyeszeti Gyar RT.
    Inventors: Csilla Horvath, Sandor Farkas, György Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Patent number: 7365083
    Abstract: Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I) wherein two of the neighboring R1, R2, R3 and R4 groups form an oxo-oxazolidine ring fused to the benzene ring of the indole nucleus, and the other two of R1, R2, R3 and R4 groups are hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups, X is NH—, Y is a —CH— group, or pharmaceutically acceptable salts thereof formed with acids or bases.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: April 29, 2008
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Csilla Horvath, Sandor Farkas, György Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Patent number: 7361670
    Abstract: Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I) wherein one of the neighboring R1, R2, R3 and R4 groups is hydroxy, and the others are each hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups, X is NH—, Y is a —CH— group, or pharmaceutically acceptable salts thereof formed with acids or bases.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: April 22, 2008
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Csilla Horvath, Sandor Farkas, György Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Patent number: 6919355
    Abstract: New Formula (I) compounds are disclosed having NR2B selective NMDA receptor antagonist activity: wherein one of the neighboring R1, R2, R3 and R4 groups is OH or NH2 and the others are each hydrogen , or two of the neighboring R1, R2 R3 and R4 groups in given case together with one or more identical or different additional hetero atom and —CH? and/or —CH2— groups forms a 5-6 membered homo- or heterocyclic ring, preferably pyrrole, pyrazole, imidazole, oxazole, oxo-oxazolidine, or 3-oxo-1,4-oxazine ring, and the other two of R1, R2, R3 and R4 groups are hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by hydroxy group, and/or in given case phenyl or phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), anilino, phenyl-(C1-C4 alkylamino), [phenyl-(C1-C4 alkyl)]-amino, benzoyl, hydroxy-diphenylmethyl, C1-C4 alkoxycarbonyl-phenoxymethyl or benzhydrylidene group, optionally substitut
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: July 19, 2005
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Csilla Horvath, Sandor Farkas, György Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Publication number: 20050113360
    Abstract: Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I) wherein two of the neighboring R1, R2, R3 and R4 groups form an oxo-oxazolidine ring fused to the benzene ring of the indole nucleus, and the other two of R1, R2, R3 and R4 groups are hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups, X is NH—, Y is a —CH— group, or pharmaceutically acceptable salts thereof formed with acids or bases.
    Type: Application
    Filed: December 28, 2004
    Publication date: May 26, 2005
    Inventors: Csilla Horvath, Sandor Farkas, Gyorgy Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Publication number: 20050113361
    Abstract: Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I) wherein one of the neighboring R1, R2, R3 and R4 groups is hydroxy, and the others are each hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups, X is NH—, Y is a nitrogen atom, or pharmaceutically acceptable salts thereof formed with acids or bases.
    Type: Application
    Filed: December 29, 2004
    Publication date: May 26, 2005
    Inventors: Csilla Horvath, Sandor Farkas, Gyorgy Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Publication number: 20050113359
    Abstract: Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I) wherein one of the neighboring R1, R2, R3 and R4 groups is hydroxy, and the others are each hydrogen atoms, R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups, X is NH—, Y is a —CH— group, or pharmaceutically acceptable salts thereof formed with acids or bases.
    Type: Application
    Filed: December 28, 2004
    Publication date: May 26, 2005
    Inventors: Csilla Horvath, Sandor Farkas, Gyorgy Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok
  • Publication number: 20040157886
    Abstract: The present invention relates to a compound of formula (I): 1
    Type: Application
    Filed: January 21, 2004
    Publication date: August 12, 2004
    Inventors: Gyorgy Domany, Csilla Horvath, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok, Eva Kovacsne Bozo, Istvan Borza, Istvan Vago, Attila Bielik, Gyorgyi Ignaczne Szendrei, Gyorgy Keseru, Sandor Farkas
  • Publication number: 20030199552
    Abstract: New Formula (I) compounds are disclosed having NR2B selective NMDA receptor antagonist activity 1
    Type: Application
    Filed: April 11, 2003
    Publication date: October 23, 2003
    Applicant: RICHTER GEDEON VEGYESZETI GYAR RT.
    Inventors: Csilla Horvath, Sandor Farkas, Gyorgy Domany, Istvan Borza, Gizella Bartane Szalai, Jozsef Nagy, Sandor Kolok